Optimization of therapeutic procedure during LDL-apheresis - verification of the computerized model in clinical practice

被引:3
|
作者
Masin, Vladimir [1 ]
Blaha, Milan
Stransky, Pravoslav
Blaha, Vladimir
Cermanova, Melanie
Maly, Radovan
Zajic, Jiri
机构
[1] Charles Univ Prague, Fac Med, Hradec Kralove, Czech Republic
[2] Fac Hosp, Hradec Kralove, Czech Republic
关键词
LDL apheresis; familial hypercholesterolemia; atherosclerosis; immunoadsorption;
D O I
10.1016/j.transci.2006.10.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
LDL-apheresis is a very effective method in the treatment of resistant hypercholesterolemia when other therapies fail. To maximize the efficacy of the use of LDL-absorbers, we created a computerized model. The aim of this study is to verify it in clinical use. Patients and methods: A therapeutic technique of immunoadsorption was used, applying a pair of Lipopak columns (Pocard, Russia). Plasma was separated by a continuous-flow plasma separator (Cobe Spectra, USA); adsorption was controlled by adsorption-desorption equipment Adasorb (Medicap, Germany). 494 LDL-apheresis procedures had been performed in nine patients with primary hypercholesterolemia in the earlier, initial study; 47 other procedures (202 therapeutic cycles) were used in this verification study. The program for procedure planning uses Microsoft Excel for Windows. Complex metabolism of the LDL-cholesterol was neglected (owing to the short-time period of the procedure) and the procedure calculated as continuous filtration. The input enterer into the program includes basic patient data (mass, height, sex and initial plasma LDL level in mmol/L). Results: The results show a very good match between calculated levels and the real laboratory results in most procedures, but in some procedures we observed minor differences (0.05 mmol/L), which was caused by procedure adjustments due to technical reasons. However, some methodological and medical details must be carefully observed (initial cholesterol level, correct calculation of plasma volume, and the precise capacity of adsorbers that must not be overshot); as they influence the correct match between calculated and real results significantly. Conclusions: Although our software uses a fairly simplified model of the LDL-cholesterol kinetics during the LDL-apheresis, it is providing a great aid in the procedure planning. It is also suitable for practical use because it only requires a few commonly used and readily available input values. 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 50 条
  • [11] A prospective trial to take advantage of PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure
    Blazek, M.
    Blaba, M.
    Masin, V.
    Blaha, V.
    Maly, J.
    Slovacek, V.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 192 - 192
  • [12] LDL-APHERESIS - POTENTIAL PROCEDURE FOR PREVENTION AND REGRESSION OF ATHEROMATOUS VASCULAR LESION
    YOKOYAMA, S
    YAMAMOTO, A
    HAYASHI, R
    SATANI, M
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1987, 51 (09): : 1116 - 1122
  • [13] LDL-apheresis: indications and clinical experience in a tertiary cardiac centre
    Archontakis, S.
    Pottle, A.
    Hakim, N.
    Ilsley, C.
    Barbir, M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (11) : 1834 - 1842
  • [14] LIPID KINETICS DURING MEMBRANE LDL-APHERESIS IN PATIENTS WITH HYPERCHOLESTEROLEMIA
    VONBAEYER, H
    KOCHINKE, F
    SCHWANER, T
    SCHWERDTFEGER, R
    SCHWARTZKOPFF, W
    ARTIFICIAL ORGANS, 1987, 11 (04) : 300 - 300
  • [15] PREVENTION OF HYPOTENSION DURING LDL-APHERESIS BY NAFAMOSTAT MESYLATE: A CASE REPORT
    Fujii, Kentaro
    Suji, Wataru
    Kato, Ai
    Yoshifuji, Ayumi
    Komatasu, Motoaki
    Ryuzaki, Munekazu
    JOURNAL OF HYPERTENSION, 2023, 41 : E443 - E444
  • [16] LDL-APHERESIS - CLINICAL-EXPERIENCE AND INDICATIONS IN THE TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA
    THIERY, J
    SEIDEL, D
    TRANSFUSION SCIENCE, 1993, 14 (03): : 249 - 259
  • [17] Angiotensin receptor antagonists during dextran sulfate LDL-apheresis are safe
    Sinzinger, H
    Chehne, F
    Ferlitsch, A
    Oguogho, A
    THROMBOSIS RESEARCH, 2000, 100 (01) : 43 - 46
  • [18] Blood level of cyclospolin during LDL-apheresis in nephrotic syndrome patients
    Nakajima, F
    Shibahara, N
    Ijiri, Y
    Ashida, A
    Ueda, H
    Katsuoka, Y
    JOURNAL OF CLINICAL APHERESIS, 1999, 14 (04) : 193 - 194
  • [19] OUTCOME COMPARISON TO TAKE ADVANTAGE OF MODIFIED PLATELETS AGGREGATION AND PFA-100 ANALYSIS TO RATIONALIZE THERAPEUTIC LDL-APHERESIS PROCEDURE
    Blazek, M.
    Blaha, M.
    Maly, J.
    Pecka, M.
    Blaha, V.
    Masin, V.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 168 - 169
  • [20] Fatty acids content of cell membranes and plasma lipoproteins during LDL-apheresis
    Bláha, V
    Havel, E
    Bláha, M
    Solichová, D
    Brátová, M
    Zadák, Z
    ATHEROSCLEROSIS, 1999, 144 : 189 - 189